Lymphocyte-Predominant Hodgkin’s Lymphoma in Children: Therapeutic Abstention After Initial Lymph Node Resection—A Study of the French Society of Pediatric Oncology
- 1 August 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (15) , 2948-2952
- https://doi.org/10.1200/jco.2003.01.079
Abstract
Purpose: To clarify treatment strategy for lymphocyte-predominant Hodgkin’s lymphoma (LPHL), the French Society of Pediatric Oncology initiated a prospective, nonrandomized study in 1988. Patients received either standard treatment for Hodgkin’s lymphoma or were not treated beyond initial adenectomy. Patients and Methods: From 1988 to 1998, 27 patients were available for study. Twenty-four patients were male, and median age was 10 years (range, 4 to 16 years). Twenty-two, two, and three patients had stage I, II, and III disease, respectively. Thirteen patients (stage I, n = 11; stage III, n = 2) received no further treatment after initial surgical adenectomy (SA). Fourteen patients received combined treatment (CT; n = 10), involved-field radiotherapy alone (n = 1), or chemotherapy alone (n = 3). The two groups were comparable for clinical status, treatment, and follow-up. Results: Twenty-three of 27 patients achieved complete remission (CR). With a median follow-up time of 70 months (range, 32 to 214 months), overall survival to date is 100%, and overall event-free survival (EFS) is 69% ± 10% (SA, 42% ± 16%; CT, 90% ± 8.6%; P < .04). If we considered only the patients in CR after initial surgery (n = 12), EFS was no longer significantly different between the two groups. Patients with residual mass after initial surgery (n = 15) had worse EFS if they did not receive complementary treatment (P < .05). Conclusion: Although based on a small number of patients, our study showed that (1) no further therapy is a valid therapeutic approach in LPHL patient in CR after initial lymph node resection, and (2) complementary treatment diminishes relapse frequency but has no impact on survival.Keywords
This publication has 20 references indexed in Scilit:
- Second Malignant Neoplasms After Treatment for Hodgkin’s Disease in Childhood or AdolescenceJournal of Clinical Oncology, 2000
- Localized Childhood Hodgkin’s Disease: Response-Adapted Chemotherapy With Etoposide, Bleomycin, Vinblastine, and Prednisone Before Low-Dose Radiation Therapy—Results of the French Society of Pediatric Oncology Study MDH90Journal of Clinical Oncology, 2000
- Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease after Administration of Rituximab (anti CD 20 Monoclonal Antibody) and Interleukin-2Leukemia & Lymphoma, 1999
- Origin of Nodular Lymphocyte-Predominant Hodgkin's Disease from a Clonal Expansion of Highly Mutated Germinal-Center B CellsNew England Journal of Medicine, 1997
- Nodular Lymphocyte Predominance Hodgkin's Disease: Long-Term Observation Reveals a Continuous Pattern of RecurrenceLeukemia & Lymphoma, 1997
- Nodular Lymphocyte Predominance Hodgkinʼs DiseaseThe American Journal of Surgical Pathology, 1994
- Lymphocyte-Predominance Hodgkin's DiseasePublished by Elsevier ,1992
- Further Phenotypic Evidence that Nodular, Lymphocyte-Predominant Hodgkinʼs Disease Is a Large B-Cell Lymphoma in EvolutionThe American Journal of Surgical Pathology, 1990
- Nodular and Diffuse Types of Lymphocyte Predominance Hodgkin's DiseaseNew England Journal of Medicine, 1988
- Lymphocyte predominant Hodgkin's disease: Clinical presentation and results of treatmentRadiotherapy and Oncology, 1984